RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+4.23%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.08B
AUM Growth
+$5.08B
(-4.1%)
Cap. Flow
+$263M
Cap. Flow
% of AUM
5.19%
Top 10 Holdings %
Top 10 Hldgs %
55.13%
Holding
68
New
14
Increased
10
Reduced
3
Closed
2
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$174M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$103M |
| 3 |
Evolent Health
EVH
|
$74.5M |
| 4 |
Taysha Gene Therapies
TSHA
|
$58.4M |
| 5 |
Apogee Therapeutics
APGE
|
$42.1M |
Top Sells
| 1 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$365M |
| 2 |
Ascendis Pharma
ASND
|
$47.4M |
| 3 |
Cytek Biosciences
CTKB
|
$30.3M |
| 4 |
Design Therapeutics
DSGN
|
$18.7M |
| 5 |
CureVac
CVAC
|
$11.2M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $1B | 19.76% | 10,719,555 -505,802 | -5% | -$47.4M |
|
2
Legend Biotech
LEGN
$6.41B
| $421M | 8.28% | 6,264,707 | – | – |
|
3
Vaxcyte
PCVX
$4B
| $402M | 7.92% | 7,891,254 | – | – |
|
|
IMGN
4
DELISTED
Immunogen Inc
IMGN
| $211M | 4.16% | 13,322,288 +10,992,330 | +472% | +$174M |
|
5
89bio
ETNB
$1.34B
| $176M | 3.47% | 11,416,948 | – | – |
|
6
Biogen
BIIB
$19.4B
| $137M | 2.7% | 532,892 | – | – |
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $130M | 2.56% | 5,676,067 | – | – |
|
|
JBIO
8
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $112M | 2.21% | 8,263,982 | – | – |
|
|
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
| $103M | 2.04% | +6,940,000 | New | +$103M |
|
|
VRNA
10
Verona Pharma
VRNA
$9.16B
| $103M | 2.03% | 6,317,990 | – | – |
|
11
Tyra Biosciences
TYRA
$675M
| $99.6M | 1.96% | 7,236,454 | – | – |
|
12
Wave Life Sciences
WVE
$1.53B
| $98.9M | 1.95% | 17,202,009 | – | – |
|
13
Geron
GERN
$893M
| $97.9M | 1.93% | 46,202,425 +14,657,619 | +46% | +$31.1M |
|
14
Day One Biopharmaceuticals
DAWN
$769M
| $95.8M | 1.89% | 7,809,852 | – | – |
|
15
Janux Therapeutics
JANX
$1.37B
| $92.4M | 1.82% | 9,165,652 +495,008 | +6% | +$4.99M |
|
16
AN2 Therapeutics
ANTX
$30.1M
| $89.3M | 1.76% | 5,551,295 +1,777,778 | +47% | +$28.6M |
|
|
INBX
17
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $86.7M | 1.71% | 4,724,207 +870,340 | +23% | +$16M |
|
18
RxSight
RXST
$370M
| $85.1M | 1.68% | 3,052,796 | – | – |
|
19
NewAmsterdam Pharma
NAMS
$2.71B
| $83.3M | 1.64% | 9,000,000 | – | – |
|
|
20
Evolent Health
EVH
$1.12B
| $74.5M | 1.47% | +2,736,680 | New | +$74.5M |
|
|
21
CureVac
CVAC
$1.21B
| $72.4M | 1.43% | 10,604,344 -1,641,611 | -13% | -$11.2M |
|
22
Axsome Therapeutics
AXSM
$6.05B
| $69.9M | 1.38% | 1,000,000 | – | – |
|
23
Cogent Biosciences
COGT
$1.69B
| $62.6M | 1.23% | 6,416,147 | – | – |
|
24
Acumen Pharmaceuticals
ABOS
$82.4M
| $62M | 1.22% | 14,932,063 +5,161,290 | +53% | +$21.4M |
|
|
25
Taysha Gene Therapies
TSHA
$797M
| $58.4M | 1.15% | +18,472,503 | New | +$58.4M |
|